FMP
Eterna Therapeutics Inc.
BTX
NASDAQ
Inactive Equity
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
0.205 USD
0.0001 (0.04876%)
About
ceo
Mr. Allen Wolff
sector
Healthcare
industry
Biotechnology
website
https://www.brooklynitx.comexchange
NASDAQ
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
CIK
0000748592
ISIN
US1140821000
CUSIP
114082100
Address
1800 Aston Ave Ste 100
Phone
17604387400
Country
US
Employee
10
IPO Date
Aug 29, 1991
Key Executives
